864754-46-1

Upstream product

• 586-76-5 4-Bromobenzoic acid 
• 33115-66-1 4-bromo-N-(4-methylpyridin-2-yl)benzamide 
• 73183-34-3 bis(pinacol)diborane 
• 586-75-4 4-chlorobenzoyl chloride 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 

Relevant academic research and scientific papers

Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma

Ibrutinib, a potent irreversible Bruton's tyrosine kinase (BTK) inhibitor, was approved by the FDA for treating mantle cell lymphoma (MCL). Although ibrutinib exhibited excellent antitumor activity, it was associated with certain adverse reactions, with o

1-substituted benzyl pyrazolopyrimidine derivative, preparation method and applications thereof

The invention discloses a 1-substituted benzyl pyrazolopyrimidine derivative, a preparation method and applications thereof, wherein the structure of the 1-substituted benzyl pyrazolopyrimidine derivative is shown as a general formula I, a general formula II or a general formula III, R1 is selected from hydrogen, C1-6 linear chain or branched chain alkyl and trihalomethyl, R2 is selected from hydrogen, halogen, nitro, C1-6 linear chain or branched chain alkyl, trifluoromethyl and cyano, R3 is selected from amino, and R4 is selected from substituted amide group. The compound has a certain BTK inhibition activity.

NOVEL HYDRAZINO COMPOUNDS AS BTK INHIBITORS

The present invention relates to novel hydrazino compounds of Formula (I) as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Described herein are cyano containing heteroaryl compounds as kinase inhibitors. Methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases described.

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds of formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.